Data from haemodynamic early phase clinical trials of GLP-1/glucagon dual agonists demonstrates Cotadutide (MEDI0382)16,17,98, Survodutide (BI 456906)19,99 and Mazdutide (IBI362)100 increase heart rate and reduce blood pressure in patients with T2D or obesity. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.